Anna G Joong

Dr. Anna G Joong

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2018 in European Heart Journal
Verified
Journal Article
Closed access
ABAlban Elouen Baruteau
Alban Elouen Baruteau
FKFlorence Kyndt
Florence Kyndt
EBElijah R Behr
Elijah R Behr
AVArja Suzanne Vink
Arja Suzanne Vink
MLMatthias Lachaud
Matthias Lachaud
VPVincent Probst
Vincent Probst
To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification. A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients ≤16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40.3% probands, median age: 8.0 [interquartile range (IQR) 9.5] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain- and loss-of-function SCN5A mutation, age ≤1 year at diagnosis in probands and age ≤1 year at diagnosis in non-probands were independent predictors of CE. In this large paediatric cohort of SCN5A mutation-positive subjects, cardiac conduction disorders were the most prevalent phenotype; CEs occurred in about one-third of genotype-positive children, and several independent risk factors were identified, including age ≤1 year at diagnosis, compound mutation, and mutation with both gain- and loss-of-function.

13 May 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
JGJustin Godown
Justin Godown
RKRichard Kirk
Richard Kirk
AJAnna G Joong
Anna G Joong
ALAshwin K. Lal
Ashwin K. Lal
MMMichael McCulloch
Michael McCulloch
JGJeffrey G. Gossett
Jeffrey G. Gossett

3 August 2017 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
AJAnna G Joong
Anna G Joong
DHDenise A. Hayes
Denise A. Hayes
BABrett R. Anderson
Brett R. Anderson
WZWarren A. Zuckerman
Warren A. Zuckerman
SCSheila J. Carroll
Sheila J. Carroll
WLWyman W. Lai
Wyman W. Lai

1 October 2019 in Current Opinion in Pediatrics
Verified
Journal Article
Closed access
LDLaura D’aDdese
Laura D’aDdese
AJAnna G Joong
Anna G Joong
MBMichael Burch
Michael Burch
EPElfriede Pahl
Elfriede Pahl
Purpose of review: To provide an international perspective and current review of pediatric heart transplantation (PHTx). Recent findings: Waitlist survival and long-term outcomes in PHTx continue to improve. Strategies to maximize donor pool utilization include ABO incompatible listing for infants and expanded donor-to-recipient weight ranges. However, there is a high degree of practice variation internationally, from listing strategies and donor acceptance practices to chronic immunosuppression regimens, long-term graft surveillance, and consideration for retransplantation. Summary: Common indications for PHTx include end-stage congenital heart disease and cardiomyopathy. Current median graft survival among PHTx recipients ranges from 13 to 22 years. Common morbidities include infection, rejection, renal dysfunction, coronary allograft vasculopathy, and posttransplant lymphoproliferative disease. International registry data, collaborative initiatives to standardize management, and multicenter studies continue to improve knowledge and advancement of the field.

18 January 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JEJonathan B Edelson
Jonathan B Edelson
ARAlexander Raskin
Alexander Raskin
MAMohammed Absi
Mohammed Absi
IAIki Adachi
Iki Adachi
OAOthman Aljohani
Othman Aljohani
ACAction Collaborators
Action Collaborators

18 October 2020 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
AJAnna G Joong
Anna G Joong
JGJeffrey G. Gossett
Jeffrey G. Gossett
EBElizabeth D. Blume
Elizabeth D. Blume
PTPhilip Thrush
Philip Thrush
EPElfriede Pahl
Elfriede Pahl
APAngira Patel
Angira Patel